Abstract
A frequent change of drug combinations may circumvent drug resistance in the treatment of patients with acute lymphoblastic leukaemia (ALL). In study COALL 85/89 201 children with high-risk ALL were randomized to receive over a period of 8 months rotational chemotherapy with six drug combinations given either in slow rotation (SR) (each combination given twice in succession) or in rapid rotation (RR) (cach combination given once with a repetition of the drug combinations). Treatment of central nervous system leukaemia consisted of cranial irradiation and intrathecal methotrexate. Both SR and RR treatment groups were then given continuation chemotherapy of oral 6-mercaptopurine and methotrexate until 2 years after the date of diagnosis. The 9-year eventfree survival (EFS) rate for the whole group is 69%±3%, and the survival rate 75%±3% at a median follow up of 5.8 years. Failure to achieve remission at day 28 was the most important prognostic factor (EFS 12%±7% vs. 75%±3% in the remission group). In the RR group, 11/100 patients were not in remission at day 28 opposed to 7/101 patients in the SR group. Children aged <1 year (6/6 relapses) or aged >=10 years had a worse prognosis (EFS 64%±5% vs. 77%±4% in patients 1–10 years old). After 5 years EFS was inferior in the RR group attributable to a significantly higher relapse rate in children with a WBC>=100/nl. The EFS at 9 years for all patients, however, is similar in both groups (SR 72%±5% vs. RR 67±5%).
Similar content being viewed by others
Abbreviations
- ALL :
-
acute lymphoblastic leukaemia
- BM :
-
bone marrow
- CNS :
-
central nervous system
- EFS :
-
event-free survival
- RR :
-
rapid rotation
- SR :
-
slow rotation
References
Bleyer, WA (1977) Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics. Cancer Treat Rep 61:1419–1425
Capizzi, RL (1974) Schedule-dependent synergism and antagonism between methotrexate and asparaginase. Biochem Pharmacol 23 [Suppl 2]:151–161
Chessels JM, Bailey CC, Richards S on behalf of the Medical Research Council Working Party on Childhood Leukaemia (1992) MRC UKALL X. The UK protocol for childhood ALL: 1985–1990. Leukemia 6 [Suppl 2]: 157–161
Clavell LA, Gelber, RD, Cohen HJ, Hitchcock-Bryan S, Cassady JR, Tarbell NJ, Blattner SR, Tantravahi R, Leavitt P, Sallan SE (1986) Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 315:657–663
De Vita VT (1983) The relationship between tumor mass and resistance to chemotherapy. Cancer 51:2109
Drescher U, Stehn M, Harms D, Kapaun P, Goertitz I, Kohlschuetter A, Janka-Schaub GE (1994) Differing length of asparagine depletion in children receiving treatment withE. coli (C-ASP)-orErwinia-asparaginase (E-ASP) (abstract). Klin Paediatr 206: 352
Gobrecht O, Goebel U, Graubner U, Gutjahr P, Schoeck V, Spaar HJ, Janka-Schaub GE fuer die COALL-Studiengruppe (1992) Einfluß von Dosisintensitaet und therapiebedinger Leukozytopenie in der Intensivtherapie auf die Prognose bei akuter lymphatischer Leukaemie im Kindesalter. Klin Paediatr 204:230–235
Goldie JH, Coldman AJ (1979) A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727–1733
Goldie JH, Coldman AJ, Gudauskas GA (1982) Rationale for the use of altermating non-cross-resistant chemotherapy. Cancer Treat Rep 66:439–449
Gustafsson G, Garwicz S, Hertz H, Johanesson G, Jonmundsson G, Moe PJ, Salmi T, Seip M, Siimes MA, Yssing M, Ahstroem L (1987) A populationbased study of childhood acute lymphoblastic leukemia diagnosed from July 1981 through June 1985 in the five nordic countries. Acta Paediatr Scand 76:781–788
Haghbin M, Murphy L, Lan CC, Clarkson BD, Thaler HT, Passe S, Burchenal J (1980) A long-term clinical follow-up of children with acute lymphoblastic leukemia treated with intensive chemotherapy regimens. Cancer 46:241–252
Harms D, Schwamborn D, Spaar HJ, Graubner U, Schoeck V, Winkler K, Janka GE for the COALL Study Group (1994) Daunorubicin-induced cell kill with 1-hour vs. 24-hour infusions: randomized comparison in newly diagnosed children with acute lymphoblastic leukemia. (abstract). Med Pediatr Oncol 23:197
Henze G, Langermann HJ, Gadner H, Schellong G, Welte K, Riehm H (1981) Ergebnisse der Studie BFM 76/79 zur Behandlung der akuten lymphoblastischen Leukaemie bei Kindern und Jugendlichen. Klin Paediatr 193: 145–154
Hryniuk WM (1987) Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 14:65–74
Janka-Schaub GE, Winkler K, Goebel U, Graubner U, Gutjahr P, Haas RJ, Juergens H, Spaar J for the COALL Study Group (1988) Rapidly rotating combination chemotherapy in childhood acute lymphoblastic leukemia: preliminary results of a randomized comparison with conventional treatment. Leukemia 2 [Suppl]:73S-78S
Janka-Schaub GE, Goebel U, Graubner U, Haas RJ, Juergens H, Spaar HJ, Winkler K (1990) Improved prognosis for chihdhood acute lymphocytic leukemia with very high white blood cell count (>100/nl) with rotation of non-cross-resistant drug combinations. Haematol Bloodtransfus 33:489–493
Janka-Schaub GE, Stuehrk H, Kortuem B, Graubner U, Juergens H, Spaar HJ, Schoeck V, Dohrn B, Bahr R, Winkler K fuer die COALL-Studiengruppe (1991) Initiales Ansprechen auf die Therapie als wichtigster prognostischer Faktor bei der akuten lymphoblastischen Leukaemie im Kindesalter. Klin Paediatr 203:231–235
Juergens H, Janka G, Ibrahim M, Tonert C, Winkler K, Goebel U (1992) Prognostic significance of exposure to intermediate-dose methotrexate in children with standard risk ALL: the COALL 82/85 experience. Haematol Bloodtransfus 34:338–352
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481
Land VJ, Shuster JJ, Crist WM, Ravindranath Y, Harris MB, Krance RA, Pinkel D, Pullen DJ (1994) Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: A Pediatric Oncology Group Study. J Clin Oncol 12:1939–1945
Lauer SJ, Camitta BM, Leventhal BG, Mahoney DH Jr, Shuster JJ, Adair S, Casper JT, Civin CI, Graham M, Kiefer G, Pullen J, Steuber CP, Kamen B (1993) Intensive alternating drug pairs for treatment of high-risk childhood acute lymphoblastic leukemia. Cancer 71:2854–2861
Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP (1991) Late cardiac effects of doxorubicin in childhood lymphoblastic leukemia. N Engl J Med 324:808–815
Meadows AT, Gordon J, Massari DJ, Littman P, Fergusson J, Moss K (1981) Declines in IQ scores and cognitive dysfunctions in children with acute lymphocytic leukaemia treated with cranial irradiation. Lancet II:1015–1018
Miller DR, Coccia PF, Bleyer WA, Lukens JN, Siegel SE, Sather HN, Hammond GD (1989) Earty response to induction therapy as a predictor of disease-free survival and late recurence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. J Clin Oncol 7: 1807–1815
Neglia JP, Meadows AT, Robison LL, Kim TH, Newton WA, Ruymann FB, Sather HN, Hammond GD (1991) Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 325:1330–1336
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG (1977) Design and analysis of randomized clinical trial requiring prolonged observation of each patient. Br J Cancer 35:1–39
Riehm H, Reiter A, Schrappe M, Berthold F, Dopfer R, Gerein V, Ludwig R, Ritter J, Stollmann B, Henze G (1986) Die Corticosteroidabhaengige Dezimierung der Leukaemiezellzahl im Blut als Prognosefaktor bei der akuten lymphoblastischen Leukaemie im Kindesalter (Therapiestudie ALL-BFM 83). Klin Paediatr 199:151–160
Riehm H, Gadner H, Henze G, Komhuber B, Lampert F, Niethammer D, Reiter A, Schellong G (1990) Results and significance of six randomized trials in four consecutive ALL-BFM studies. Haematol Bloodtransfus 33: 439–450
Rivera GK, Aur RJ, Dahl GV, Pratt CB, Wood A, Avery TL (1980) Combined VM-26 and cytosine arabinoside in treatment of refractory childhood lymphocytic leukemia. Cancer 45: 1284–1288
Rivera GK, Raimondi SC, Hancock ML, Behm FG, Pui CH, Abromowitch M, Mirro J Jr, Ochs JS, Look AT, Williams DL, Murphy SB, Dahl GV, Kalwinsky DK, Evans WE, Kun LE, Simone JV, Crist WM (1991) Improved outcome in childhood acute lymhoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 337:61–66
Sallan SE, Camitta BM, Cassady JR, Nathan DG, Frei E III (1978) Intermittent combination chemotherapy with adriamycin for childhood acute lymphoblastic leukemia: clinical results. Blood 51:425–433
Schorin MA, Blattner S, Gelber RD, Tarbell NJ, Donnelly M, Dalton V, Cohen HJ, Sallan SE (1994) Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital acute lymphoblastic leukemia consortium protocol 85–01. J Clin Oncol 12:740–747
Steinherz PG, Gaynon P, Miller DR, Reaman G, Bleyer A, Finklestein J, Evans RG, Meyers P, Steinherz LJ, Sather H, Hammond D (1986) Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen — a new intensive therapy protocol: A report form the Childrens Cancer Study Group. J Clin Oncol 4:744–752
Wells RJ, Feusner J, Devney R, Woods WG, Provisor AJ, Cairo MS, Odom LF Nachman J, Jones GR, Ettinger LJ, Capizzi RL (1985) Sequential highdose cytosine arbinoside-asparaginase treatment in advanced childhood leukemia. J Clin Oncol 3:998–1004
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Janka-Schaub, G.E., Harms, D., Goebel, U. et al. Randomized comparison of rotational chemotherapy in high-risk acute lymphoblastic leukaemia of childhood — follow up after 9 years. Eur J Pediatr 155, 640–648 (1996). https://doi.org/10.1007/BF01957144
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01957144